NCT03030378 2026-03-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT01468896 2026-03-18
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02483312 2025-12-01
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
University Health Network, Toronto
Phase 1 Active not recruiting